Elige el tipo de letra:
 Arimo
 Merriweather
 Mukta Malar
 Open Sans Condensed
 Rokkitt
 Source Sans Pro
 Login


 Español 
 Français 
 English 
 Português 

[Valid RSS] RSS
bar

Base de datos - (CIANE)

Presentación de esta base de datos documental (Sitio web de CIANE)
Actualmente 3111 registros
Canal de YouTube (tutorial)

https://ciane.net/id=2303

Creado el : 03 Jan 2009
Alterado em : 03 Jan 2009

 Editar este registro
¡Sólo siga este enlace si tiene una contraseña de editor!


Compartir : Facebook logo   Tweeter logo   Especializado

Ficha bibliográfica (sin autores) :

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510.Click here to read

Autores :

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P.

Año de publicación :

2007

URL(s) :

http://mrw.interscience.wiley.com/cochrane/clsysre…

Résumé (français)  :

Abstract (English)  :

BACKGROUND: Antiretroviral drugs (ARV) reduce viral replication and can reduce mother-to-child transmission of HIV either by lowing plasma viral load in pregnant women or through post-exposure prophylaxis in their newborns. In rich countries, highly active antiretroviral therapy (HAART) has reduced the vertical transmission rates to around 1-2%, but HAART is not yet widely available in low and middle income countries. In these countries, various simpler and less costly antiretroviral regimens have been offered to pregnant women or to their newborn babies, or to both.

OBJECTIVES: To determine whether, and to what extent, antiretroviral regimens aimed at decreasing the risk of mother-to-child transmission of HIV infection achieve a clinically useful decrease in transmission risk, and what effect these interventions have on maternal and infant mortality and morbidity.

SEARCH STRATEGY: We sought to identify all relevant studies regardless of language or publication status by searching the Cochrane HIV/AIDS Review Group Trials Register, The Cochrane Library, Medline, EMBASE and AIDSearch and relevant conference abstracts. We also contacted research organizations and experts in the field for unpublished and ongoing studies. The original review search strategy was updated in 2006.

SELECTION CRITERIA: Randomised controlled trials of any antiretroviral regimen aimed at decreasing the risk of mother-to-child transmission of HIV infection compared with placebo or no treatment.

DATA COLLECTION AND ANALYSIS: Two authors independently selected relevant studies, extracted data and assessed trial quality. For the primary outcomes, we used survival analysis to estimate the probability of infants being infected with HIV (the observed proportion) at various specific time-points and calculated efficacy at a specific time as the relative reduction in the proportion infected. Efficacy, at a specific time, is defined as the preventive fraction in the exposed group compared to the reference group, which is the relative reduction in the proportion infected: 1-(Re/Rf). For those studies where efficacy and hence confidence intervals were not calculated, we calculated the approximate confidence intervals for the efficacy using recommended methods. For analysis of results that are not based on survival analyses we present the relative risk for each trial outcome based on the number randomised. No meta-analysis was conducted as no trial assessed the identical drug regimens.

MAIN RESULTS: Eighteen trials including 14,398 participants conducted in 16 countries were eligible for inclusion in the review.

[…]

AUTHORS’ CONCLUSION: Short courses of antiretroviral drugs are effective for reducing mother-to-child transmission of HIV and are not associated with any safety concerns in the short-term. A combination of ZDV and 3TC given to mothers in the antenatal, intrapartum and postpartum periods and to babies for a week after delivery or a single dose of NVP given to mothers in labour and babies immediately after birth may be most effective. Where HIV infected women present late for delivery, post-exposure prophylaxis with a single dose of NVP immediately after birth plus ZDV for the first 6 weeks of life is beneficial. The long term implications of the emergence of resistant mutations following the use of these regimens require further study.

Sumário (português)  :

Resumen (español)  :

Comentarios :

Argument (français) :

Argument (English):

Researchers theorized that a course of antiretroviral drugs (ARV) given to pregnant women and their newborn babies could reduce the risk of mother-to-child transmission.

Argumento (português):

Argumento (español):

Palabras claves :

➡ VIH

Autor de este registro :

Bernard Bel — 03 Jan 2009

Debate (mostrar sólo español)
 
➡ Sólo para usuarios identificados



 He leído la política de debate y acepto las condiciones
[Ocultar la póliza]

➡ Carta de debate

1) Los comentarios pretenden aclarar el contenido del artículo o proporcionar enlaces a información adicional sobre el tema
2) Los comentarios son públicos y las opiniones expresadas son responsabilidad exclusiva del autor
3) Evite cualquier anécdota o relato personal
4) Los comentarios que se salgan del tema o contengan un lenguaje inaceptable serán eliminados sin previo aviso

barre

Realizar otra consulta de expertos --- Realice otra consulta sencilla

Creación de un registro --- Importación de registros

Gestión de usuarios --- Salvaguardar la base de datos --- Contacto

bar

Esta base de datos creada por la Alliance francophone pour l'accouchement respecté (AFAR) está gestionada
por el Collectif interassociatif autour de la naissance (CIANE, https://ciane.net).
Se nutre de las contribuciones de voluntarios interesados en compartir información científica.
Si está de acuerdo con este proyecto, puede ayudarnos de varias maneras:
(1) convertirse en colaborador de esta base de datos, si tiene alguna experiencia en documentación
(2) ou apoio financeiro CIANE (veja abaixo)
(3) o hacerse miembro de otra asociación afiliada al CIANE.
Inicie sesión o cree una cuenta para seguir los cambios o convertirse en editor.
Contacta con bibli(arobase)ciane.net para más información.

Valid CSS! Valid HTML!
Donar a CIANE (haga clic en 'Faire un don') nos ayudará a mantener y desarrollar
sitios y bases de datos públicas para apoyar las decisiones informadas de los progenitores
y profesionales de la salud con respecto al parto